Mayne Pharma Group Ltd (ASX: MYX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mayne Pharma Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $438.98 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 85.07 million
Earnings per share -3.178
Dividend per share 0.04
Year To Date Return -10.89%
Earnings Yield N/A
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Mayne Pharma Group Ltd (ASX: MYX)
    Latest News

    Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
    Share Gainers

    Why Appen, Mayne Pharma, Playside, and PYC shares are storming higher

    These shares are ending the week on a positive note. But why?

    Read more »

    A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
    Broker Notes

    3 ASX 300 shares receiving broker upgrades today (one with 25% potential upside)

    This trio of ASX 300 stocks released their earnings results for 1H FY24 yesterday.

    Read more »

    Man drawing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why Alumina, Kogan, Mayne Pharma, and Suncorp shares are racing higher

    These ASX shares are having a strong session on Monday.

    Read more »

    A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
    Share Gainers

    Why Imugene, Mayne Pharma, Westpac, and Wildcat shares are storming higher

    These ASX shares are starting the week strongly.

    Read more »

    A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
    Share Market News

    Which ASX All Ords shares have company directors been buying up?

    ASX investors typically take this as a good sign, so let's review the All Ords stocks involved.

    Read more »

    Smiling couple looking at a phone at a bargain opportunity.
    Share Gainers

    Why Evolution, Latin Resources, Mayne Pharma, and Paladin Energy shares are pushing higher

    These ASX shares are having a strong session. But why?

    Read more »

    A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
    Healthcare Shares

    3 ASX healthcare shares up 10% to 22% on news

    These healthcare shares are catching the eye on Wednesday. But why?

    Read more »

    ASX 200 investor looking frustrated at falling share price whilst sitting at desk
    Healthcare Shares

    Why did this ASX All Ords share plunge 18% today?

    It's another day deep in the red for this healthcare company.

    Read more »

    A man looks down with fright as he falls towards the ground.
    Share Fallers

    Why Austal, Chalice Mining, Fortescue, and Mayne Pharma shares are dropping today

    These ASX shares are under pressure on Friday.

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why 4DS, Chalice Mining, Mayne Pharma, and Webjet shares are sinking today

    These ASX shares are out of form on Thursday. What's going on?

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Earnings Results

    Guess which ASX 300 healthcare stock just tanked 20%

    FY23 was a year of transformation for this company.

    Read more »

    young boys open mouthed in front of shares graph
    Share Market News

    Returning capital: These ASX companies have been buying back their shares in 2023

    Do you own any of these capital-returning shares?

    Read more »

    Frequently Asked Questions

    Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.

    Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    18 Jan 2023 $0.0272 100.00% Special Cash 27 Jan 2023

    MYX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mayne Pharma Group Ltd

    Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.

    Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market. 

    MYX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 May 2024 $5.16 $-0.32 -5.84% 376,596 $5.38 $5.39 $5.14
    24 May 2024 $5.48 $0.07 1.29% 423,323 $5.66 $5.89 $5.42
    23 May 2024 $5.41 $0.07 1.31% 219,442 $5.26 $5.51 $5.25
    22 May 2024 $5.34 $-0.11 -2.02% 229,399 $5.43 $5.59 $5.33
    21 May 2024 $5.45 $-0.29 -5.05% 502,180 $5.73 $5.73 $5.45
    20 May 2024 $5.74 $-0.63 -9.89% 960,647 $6.19 $6.19 $5.38
    17 May 2024 $6.37 $0.12 1.92% 221,592 $6.26 $6.48 $6.14
    16 May 2024 $6.25 $0.15 2.46% 676,149 $6.03 $6.28 $5.94
    15 May 2024 $6.10 $-0.56 -8.41% 285,874 $6.62 $6.62 $6.10
    14 May 2024 $6.66 $-0.41 -5.80% 759,072 $7.03 $7.03 $6.28
    13 May 2024 $7.07 $0.06 0.86% 72,172 $7.01 $7.20 $7.01
    10 May 2024 $7.01 $-0.11 -1.54% 85,754 $7.14 $7.17 $7.00
    09 May 2024 $7.12 $-0.02 -0.28% 159,902 $7.08 $7.21 $7.08
    08 May 2024 $7.14 $-0.13 -1.79% 117,353 $7.13 $7.16 $7.04
    07 May 2024 $7.27 $0.00 0.00% 87,693 $7.27 $7.43 $7.23
    06 May 2024 $7.27 $-0.10 -1.36% 85,109 $7.38 $7.40 $7.22
    03 May 2024 $7.37 $0.36 5.14% 366,226 $7.01 $7.46 $6.99
    02 May 2024 $7.01 $0.21 3.09% 385,070 $6.88 $7.04 $6.80
    01 May 2024 $6.80 $-0.17 -2.44% 528,363 $6.80 $6.90 $6.76
    30 Apr 2024 $6.97 $-0.14 -1.97% 92,661 $7.15 $7.15 $6.94
    29 Apr 2024 $7.11 $0.18 2.60% 112,429 $6.97 $7.17 $6.97

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    08 Dec 2023 Shawn O'Brien Issued 290,554 $1,699,740
    Issue of securities. 6,54,657 Rights
    01 Dec 2023 Frank Condella Buy 7,154 $38,811
    On-market trade.
    25 Oct 2023 Kathryn MacFarlane Buy 18,000 $69,120
    On-market trade.
    24 Oct 2023 Shawn O'Brien Buy 37,041 $140,917
    On-market trade.
    23 Oct 2023 Ann Custin Buy 6,037 $20,207
    On-market trade.
    20 Oct 2023 Ann Custin Buy 6,250 $20,920
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Frank Condella Non-Executive DirectorNon-Executive Chairman May 2018
    Mr Condella is a US resident has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes Chief Executive Officer of Juniper Pharmaceuticals, a US publicly-listed CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as Chief Executive Officer of Skyepharma Plc, President of European operations at IVAX (Teva), Chief Executive Officer of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella's previous board experience includes Chairman of Skyepharma Plc until it merged with Vectura, Vice Chairman of Vectura Plc, Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, Independent Director of Fertin Pharma A/S, Independent Director of Palladio Biosciences Inc and Chairman of the PKD Foundation. He is Chairman of People Commitee.
    Professor Bruce Gregory Robinson Non-Executive Director Aug 2014
    Mr Robinson is a practising Endocrinologist at Sydney's Royal North Shore Hospital, is Former Dean of University of Sydney's Sydney Medical School. Professor Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, Professor Robinson has been Chairman of Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam. He is a Non-Executive Director of Cochlear Limited, Lorica and QBiotics Group Limited. He is a Board Member of the Woolcock Institute, is Chair of National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce.Prof Robinson is Chair of the Science, Technology and Medical Committee.
    Mr Patrick J Blake Non-Executive Director Jun 2018
    Mr Blake is a US resident, has over 30 years of global healthcare industry experience including more than 20 years at McKesson Corporation, one of the healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation. Most recently, he was Executive Vice President of McKesson Corporation and Group President of McKesson Technology Solutions which services the health IT needs of hospitals and health systems, payers, physicians, homecare agencies, retail pharmacies and manufacturers, a position he held from 2009 until 2017. Previously, he was President of McKesson Specialty Health, a business focused on the US specialty/biotech sector which was McKesson's business for three years during his leadership. He was also President of Customer Operations for McKesson Pharmaceutical (US) from 2000 to 2006, leading commercial sales and operations for the wholesale distribution of branded, specialty and generic pharmaceuticals and other related products.Mr Blake is a member of the Risk Committee and People Committee.
    Ms Ann Custin Non-Executive Director Mar 2022
    Ms Custin is a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin was Board Director and CFO of Siemens Medical Solutions, a leading medical technology company with EUR20b in revenues. Previously, she was Chief Operating and Financial Officer of Scient'x Group and President and CEO of USA Draeger Medical Systems. Ms Custin is a Non-Executive Director Establishment Labs Holdings Inc (NASDAQ:ESTA).Ms Custin is Chair of the Risk Committee
    Dr Kathryn MacFarlane Non-Executive Director Feb 2022
    Dr MacFarlane is a US resident, has more than 30 years of experience in the pharmaceutical industry. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women's Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at ParkeDavis.Dr MacFarlane is a member of the of the Science, Technology and Medical Committee.
    Mr David Petrie Non-Executive Director Sep 2022
    Mr Petrie is an accomplished M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He has worked on more than 100 transactions across a range of market sectors including healthcare.Mr Petrie is a member of the Risk and People Committee.
    Mr Shawn Patrick O'Brien Chief Executive OfficerManaging Director Oct 2022
    Mr O'Brien has more than 35 years of global pharmaceutical industry experience building enterprises. He was a founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. He was previously the Chairman and CEO of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals, Profectus BioSciences and Solstice Neurosciences. Mr O'Brien held multiple senior leadership roles at AstraZeneca, one of the global pharmaceutical companies. At AstraZeneca he was responsible for key brands such as FASLODEX, SYMBICORT, PULMICORT and SEROQUEL which all became billion-dollar brands.
    Ms Anne Nicole Lockwood Non-Executive Director Nov 2023
    --
    Ms Laura Loftus Company Secretary Mar 2020
    -
    Laura Loftus Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 10,761,314 12.90%
    HSBC Custody Nominees (Australia) Limited 7,245,424 8.70%
    J P Morgan Nominees Australia Pty Limited 6,792,556 8.10%
    Mr Bruce Mathieson And Related Entities 5,292,066 6.30%
    Estetra Srl <No 1 Account> 4,221,815 5.10%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 3,369,950 4.00%
    Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C> 2,359,715 2.80%
    National Nominees Limited 2,052,695 2.50%
    Bnp Paribas Noms Pty Ltd <Drp> 1,954,119 2.30%
    Gft 2 Co Pty Limited <Gft 2 A/C> 1,295,569 1.60%
    Ivl Group Pty Ltd 800,000 1.00%
    Vivnat (Curtin) Pty Ltd 750,000 0.90%
    R & R Corbett Pty Ltd <R C Corbett Family A/C> 522,028 0.60%
    Y S Chains Pty Ltd 500,000 0.60%
    Retzos Executive Pty Ltd <Retzos Executive S/Fund A/C> 465,000 0.60%
    Mr Kon Tzimokas 400,000 0.50%
    Wal Assets Pty Ltd <The La Wilson Property A/C> 354,500 0.40%
    Birbal Investments Pty Ltd 300,000 0.40%
    Mr Yunsong Zhang 300,000 0.40%
    Belgravia Strategic Equities Pty Ltd 295,250 0.40%

    Profile

    since

    Note